ClinicalTrials.gov
ClinicalTrials.gov Menu

Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00647023
Recruitment Status : Terminated
First Posted : March 31, 2008
Last Update Posted : March 31, 2008
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
Hvidovre University Hospital

Brief Summary:
The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose. The incretin response is attenuated in subjects with type 2 diabetes and other conditions associated with insulin resistance. Polycystic ovary syndrome (PCOS) is characterised by irregular periods and increased androgen levels. It is the most common endocrine disorder amongst young women at fertile age, and the most common cause of female infertility. Insulin resistance plays an important role in the development of the disease, and women with PCOS are at increased risk of developing tyoe 2 diabetes. the incretin hormones have not previously been investigated in women with PCOS, and the purpose of the present study was to investigate the secretion of the two most important incretin hormones Glucose-like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP) during a three hour oral glucose tolerance test.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Drug: metformin Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Primary Purpose: Basic Science
Study Start Date : February 2004
Actual Primary Completion Date : May 2006
Actual Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: A Drug: metformin
1000 mg metformin x 2 daily during 8 months




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who fulfill the Rotterdam criteria for PCOS. Age 18-38

Exclusion Criteria:

  • Other endocrine diseases or diseases known to influence glucose/insulin/fat metabolism
  • Oral contraceptive administration within three months of study start

Responsible Party: Incretin secretion in women with PCOS, Pernille Fog Svendsen
ClinicalTrials.gov Identifier: NCT00647023     History of Changes
Other Study ID Numbers: Incretins and PCOS
First Posted: March 31, 2008    Key Record Dates
Last Update Posted: March 31, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Syndrome
Polycystic Ovary Syndrome
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs